12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Company News  |  Deals

Allos, Spectrum Pharmaceuticals deal

Spectrum extended to 5 p.m. EDT on May 24 from May 10 its tender offer to acquire cancer company Allos for $1.82 per share up front, plus a contingent value right of $0.11 related to European...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >